Terapevticheskii arkhiv · 2008
[Administration of afobasol for correction of mental disorders in celiac disease patients].
Аннотация на английскомСтатьяНазвание и аннотация: Оригинал на русском
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Oreshko L S
Аннотация
AIM: To study afobasol efficacy in anxiety and neurotization correction in patients with celiac disease (CD).
MATERIAL AND METHODS: We examined 17 CD patients with mental diseases (anxiety, anxiophobic and neurotic disorders) aged 35.3 +/- 3.5 years. Personal and situational anxiety levels were assessed with multivariate questionnaire of the integrative anxiety test, neurotization--with Wasserman's questionnaire. Mental diseases were treated for 4 weeks with afobasol in a daily dose 30 mg.
RESULTS: An initial level of personal anxiety was elevated in 100% patients, of situational anxiety--in 66.7%. These kinds of anxiety (most of all general, emotional discomfort, asthenic and phobic components) were treated with a positive effect. Neurotization was high in 11 patients. The treatment was effective in 6 of them. Side effects were not noted. The highest reduction was seen in emotional discomfort, asthenic component and anxiety.
CONCLUSION: Afobasol is effective in management of mental diseases in patients with celiac disease.
MATERIAL AND METHODS: We examined 17 CD patients with mental diseases (anxiety, anxiophobic and neurotic disorders) aged 35.3 +/- 3.5 years. Personal and situational anxiety levels were assessed with multivariate questionnaire of the integrative anxiety test, neurotization--with Wasserman's questionnaire. Mental diseases were treated for 4 weeks with afobasol in a daily dose 30 mg.
RESULTS: An initial level of personal anxiety was elevated in 100% patients, of situational anxiety--in 66.7%. These kinds of anxiety (most of all general, emotional discomfort, asthenic and phobic components) were treated with a positive effect. Neurotization was high in 11 patients. The treatment was effective in 6 of them. Side effects were not noted. The highest reduction was seen in emotional discomfort, asthenic component and anxiety.
CONCLUSION: Afobasol is effective in management of mental diseases in patients with celiac disease.